Int J Oral Maxillofac Implants. 2020 Sep/Oct;35(5):939-947. doi: 10.11607/jomi.8354.
This study investigated the effects of bisphosphonates, namely, alendronate and zoledronate, on the osteogenic activity of osteoprogenitor cells cultured on titanium surfaces at therapeutic doses in order to assess if altered osteoblastogenesis could compromise osseointegration and contribute to etiopathogenesis of painful disorders such as bisphosphonates-related osteonecrosis of the jaw (BRONJ) following implant placement.
MC3T3-E1 Subclone 4 cells were utilized in this study. Therapeutic doses of alendronate and zoledronate were calculated based on reported peak plasma concentrations. The viability, proliferation, adhesion, and mineralization potential of cells was assessed using a LIVE/DEAD stain, alamarBlue assay, immunofluorescence microscopy, and Alizarin Red S staining, respectively.
Therapeutic doses of zoledronate negatively affected cell viability, whereas therapeutic doses of alendronate significantly enhanced cell differentiation and the amount of bone formation compared with the control.
The findings of this study may provide some insight into the pathogenesis of BRONJ development following implant placement in patients treated with zoledronate and may have promising implications toward improved wound healing and osseointegration in patients treated with alendronate.
本研究旨在探讨双膦酸盐(即阿仑膦酸钠和唑来膦酸)在治疗剂量下对培养在钛表面的成骨前体细胞的成骨活性的影响,以评估成骨细胞生成的改变是否会影响骨整合,并导致植入后发生与双膦酸盐相关的颌骨坏死(BRONJ)等疼痛性疾病的发病机制。
本研究使用了 MC3T3-E1 亚克隆 4 细胞。根据报道的峰值血浆浓度计算了阿仑膦酸钠和唑来膦酸的治疗剂量。通过 LIVE/DEAD 染色、alamarBlue 检测、免疫荧光显微镜和茜素红 S 染色分别评估细胞的活力、增殖、黏附和矿化潜力。
治疗剂量的唑来膦酸对细胞活力有负面影响,而治疗剂量的阿仑膦酸钠与对照组相比,显著增强了细胞分化和骨形成的量。
本研究的结果可能为接受唑来膦酸盐治疗的患者植入后发生 BRONJ 发展的发病机制提供一些见解,并可能对接受阿仑膦酸钠治疗的患者的伤口愈合和骨整合有积极的影响。